Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses

This article was originally published in PharmAsia News

Executive Summary

Japan's second-largest drug maker Astellas estimates net profit is down by 27 percent to ¥125 billion ($1.375 billion) for fiscal year 2009, due largely to decreasing sales from patent losses in major products Prograf (tacrolimus) and Flomax (tamsulosin) and increasing research and development expenses to cultivate new products
Advertisement

Related Content

Astellas Takes First Steps In India With Prograf
Astellas Takes First Steps In India With Prograf
Astellas-Maxygen Joint Venture Highlights Japan's Creative Alliances - BIO Asia Conference
Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
Advertisement
UsernamePublicRestriction

Register

SC074164

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel